<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="154558">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01706991</url>
  </required_header>
  <id_info>
    <org_study_id>rebiscan-003</org_study_id>
    <nct_id>NCT01706991</nct_id>
  </id_info>
  <brief_title>Amblyopia and Strabismus Detection Using a Pediatric Vision Scanner</brief_title>
  <official_title>MEPEDS New Device Pediatric Vision Scanner</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rebiscan, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Southern California</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Rebiscan, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this project is to compare the performance of the Pediatric Vision Scanner
      (PVS) with the Gold Standard Examination to determine the effectiveness of the PVS at
      detecting amblyopia and strabismus. All tests and observations will be done at a single
      visit over the course of approximately 30 minutes.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case Control, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Binocularity score</measure>
    <time_frame>Day 1</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Presence of amblyopia risk factors</measure>
    <time_frame>Day 1</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">32</enrollment>
  <condition>Amblyopia</condition>
  <condition>Strabismus</condition>
  <arm_group>
    <arm_group_label>Normal Controls</arm_group_label>
    <description>Structurally normal eye with equal visual acuity and normal stereopsis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Referral required</arm_group_label>
    <description>Diagnosed with amblyopia or constant strabismus, categorized based on the GSE.
Amblyopia:
VA &lt;20/40 and 2 logMAR lines difference in normal eye
Mild amblyopia (&gt;20/40)
Moderate amblyopia (20/40 and &lt;20/100)
Severe amblyopia (≥20/100 or worse)
Bilateral amblyopia: &gt;4 years age VA&lt;20/40 OU including high hyperopia or high astigmatism.
Strabismus:
Constant: &gt;2 PD at near and or distance.
Intermittent: strabismus that could be controlled intermittently either through fusional mechanisms or a compensatory head position.
Amblyogenic factor categorization:
'Anisometropia'- (1.5 Diopters (D) or more difference in refractive error between the two eyes.
'hypermetropia' (≥3.5 D),
'myopia' (≥-4.0 D),
'astigmatism' (≥1.5 D).
'structural abnormalities' of the eye will not be excluded, but will be considered to have vision loss if visual acuity is 20/40 or worse.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Borderline</arm_group_label>
    <description>(no long-term harm to patient if referral is delayed, however the patient does have conditions that might benefit from monitoring): Equal visual acuity and no structural abnormality with any of the following: Amblyogenic factor, intermittent strabismus, structural abnormalities, refractive error, reduced stereopsis.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Pediatric Vision Scanner eye scan</intervention_name>
    <description>Subject is scanned with a 2.5 second pediatric vision scanner device test.</description>
    <arm_group_label>Normal Controls</arm_group_label>
    <arm_group_label>Referral required</arm_group_label>
    <arm_group_label>Borderline</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Children presenting for ophthalmic exam at eye clinic.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Children aged 6 months to 6 years

          -  Signed Informed consent by parent or guardian

          -  Meet all inclusion criteria.

        Exclusion Criteria:

          -  Children with a history of developmental delay or cognitive deficit

          -  Children unable to complete the GSE (including visual acuity testing)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>6 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rohit Varma, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Southern California</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Doheny Eye Institute</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Loudon SE, Rook CA, Nassif DS, Piskun NV, Hunter DG. Rapid, high-accuracy detection of strabismus and amblyopia using the pediatric vision scanner. Invest Ophthalmol Vis Sci. 2011 Jul 7;52(8):5043-8. doi: 10.1167/iovs.11-7503.</citation>
    <PMID>21642624</PMID>
  </reference>
  <verification_date>October 2012</verification_date>
  <lastchanged_date>October 12, 2012</lastchanged_date>
  <firstreceived_date>October 5, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Amblyopia</mesh_term>
    <mesh_term>Strabismus</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
